Related Experiment Video
Updated: Feb 18, 2026
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
The Effect of Granulocyte Colony-Stimulating Factor on the Progression of Atherosclerosis in Animal Models: A
Manli Liu1,2, Kejian Liu3,4, Dongdong Chen1,2
1Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Insights
Granulocyte colony-stimulating factor (G-CSF) therapy may reduce atherosclerosis progression by decreasing lesion area in animal models. This finding offers insights for future preclinical and clinical studies on G-CSF for atherosclerosis treatment.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Inflammatory Diseases
Background:
- Atherosclerosis is a prevalent inflammatory condition affecting arteries.
- Stem cell therapies show promise in improving cardiac function post-myocardial infarction.
- Granulocyte colony-stimulating factor (G-CSF) mobilizes stem cells, suggesting potential therapeutic applications for atherosclerosis.
Purpose of the Study:
- To evaluate the efficacy of G-CSF in inhibiting atherosclerosis progression using a meta-analysis of animal models.
- To provide a reference for preclinical research and future human clinical trials investigating G-CSF for atherosclerosis.
Main Methods:
- A systematic literature search was conducted across multiple databases.
- A meta-analysis of seven relevant studies was performed using a random-effect model.
- Statistical analyses were executed using Review Manager Version 5.2 and Stata 12.0.
Main Results:
- G-CSF therapy demonstrated a significant reduction in atherosclerotic lesion area (WMD: 7.29%, P=0.006).
- No significant impact of G-CSF on serum cholesterol or triglyceride levels was observed (P>0.54).
- Animal type (e.g., rabbits) and G-CSF administration frequency (>20) were identified as significant factors influencing lesion area changes via metaregression analysis.
Conclusions:
- G-CSF treatment shows potential in inhibiting the progression of atherosclerosis in preclinical animal models.
- Further research is warranted to translate these findings into effective human therapies for atherosclerosis.
Background:
Atherosclerosis is a common inflammatory disease. Stem cell and endothelial progenitor cell treatments can improve cardiac function after myocardial infarction. Granulocyte colony-stimulating factor (G-CSF) is a mobilisation agent, mobilising stem cells from the bone marrow to circulation in the blood. G-CSF may constitute a treatment of atherosclerosis. We have conducted meta-analysis to evaluate the current evidence for the effect of G-CSF on the progression of atherosclerosis in animal models and to provide reference for preclinical experiments and future human clinical trials of atherosclerosis treatment.
Methods:
We searched several databases and conducted a meta-analysis across seven articles using a random-effect model. All statistical analyses were performed using Review Manager Version 5.2 and Stata 12.0.
Results:
We found that G-CSF therapy was associated with reduced atherosclerotic lesion area (weighted mean difference (WMD): 7.29%; 95% confidence interval (CI): 2.06-12.52%; P = 0.006). No significant differences in total serum cholesterol (P = 0.54) and triglyceride levels (P = 0.95) were noted in G-CSF treatment groups compared with controls. Multivariable metaregression analysis revealed that the animal type (rabbit, P = 0.022) and frequency of G-CSF administration (>20, P = 0.007) impacted the atherosclerotic lesion area changes.
Conclusion:
The meta-analysis suggested that G-CSF treatment might inhibit the progression of atherosclerosis in animal models.
Related Concept Videos
01:26Atherosclerosis III: Management
01:38Inflammation
01:30Atherosclerosis I: Introduction
01:01Regulation of Hematopoietic Stem Cells